This study is for kids and teens with short height due to certain growth issues. These issues include Turner Syndrome (TS), SHOX-D (short stature homeobox-containing gene deficiency), Small for Gestational Age (SGA), and Idiopathic Short Stature (ISS). The trial checks the effectiveness of a new weekly medicine called lonapegsomatropin compared to a daily one called somatropin. Participants will be either on lonapegsomatropin for 2 years or somatropin for 1 year, then switch to lonapegsomatropin for another year. The trial will be in several countries including the U.S., France, and South Korea.
Key Points:- This study lasts for 2 years with regular check-ups.
- Participants must not have had growth treatments before.
- Participants should be between 2 and 18 years old and not in puberty yet.
It's important to note that the trial involves genetic testing and excludes those with certain health problems. Parents or guardians must agree to the child's participation, and the child should agree too if required.